According to analysts polled by FactSet, Wall Street is forecasting revenue of $12.28 billion, a marginal decrease from the $12.34 billion reported in the same period last year. Adjusted earnings are projected to hit $1.23 per share, down from $1.67 a year ago. Despite these cooling figures, investor sentiment has remained resilient; the stock has climbed 26% over the past three months, recently trading near $57.66.

Navigating the Patent Cliff

The primary concern for shareholders is the looming loss of exclusivity for several legacy drugs. Management is expected to provide clarity on how the company intends to offset the resulting sales erosion. Additionally, the blockbuster blood thinner Eliquis faces upcoming margin pressure due to Medicare price negotiations that recently took effect. Investors are seeking specific guidance on how these federal pricing mandates will impact the company’s long-term revenue trajectory starting in 2026.

To counter these headwinds, Bristol Myers Squibb is leaning heavily on its newer immuno-oncology and specialty portfolio. Analysts are looking for sustained growth from three critical assets to prove the company can transition away from its older high-volume treatments:

• Breyanzi, a cell therapy for specialized cancer treatment.
• Reblozyl, used for treating anemia in specific blood disorders.
• Camzyos, a cardiac medication targeting obstructive hypertrophic cardiomyopathy.

The success of these newer launches is vital for the company to maintain its market position as its legacy portfolio fades. Thursday’s report will serve as a bellwether for whether this transition is progressing fast enough to satisfy the market's growth expectations.